Characterization of a novel AmpC-type plasmid-mediated beta-lactamase from an Escherichia coli strain isolated in China.
The aim of this work was to study the phenotypic and molecular characterization of a novel plasmid-mediated AmpC beta-lactamase from Escherichia coli E384. Conjugation experiments, isoelectric focusing, pulsed-field gel electrophoresis, plasmid profiling, and Southern blot as well as PCR, sequencing techniques, and susceptibility testing were carried out to investigate the underlying mechanism of resistance. The kinetic parameters were determined to characterize the novel enzyme. MIR-4 beta-lactamase, pI 8.2, is a novel variant with four substitutions of amino acids compared with the sequence of MIR-1. E. coli E384 displays resistance to eight beta-lactam antimicrobial agents and three fluoroquinolones. The minimal inhibitory concentrations of beta-lactam in combination with beta-lactamase inhibitors show no significant synergy. Kinetic parameters suggest that the novel enzyme effectively hydrolyzes broad-spectrum beta-lactams. The same hybridization signal was detectable only in the 54-kb plasmid band that hybridized with the bla (CTX-M)- and bla(ampC)-specific probes. This is the first description of a plasmid-mediated MIR-4 enzyme in China. This study illustrates the importance of molecular surveillance in tracking AmpC-producing strains at general hospitals and emphasizes the need for epidemiological monitoring.
Wang
Qian
Q
Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China.
Cheng
Jun
J
Chen
Yan
Y
Ye
Ying
Y
Li
Jia-Bin
JB
Zhang
Xue-Jun
XJ
D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000096:biosynthesis* / Q000737:chemistry / Q000235:genetics* / Q000302:isolation & purification; D015139:Blotting, Southern; D002681:China; D003227:Conjugation, Genetic; D004269:DNA, Bacterial / Q000737:chemistry / Q000235:genetics; D016521:Electrophoresis, Gel, Pulsed-Field; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology* / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000382:microbiology; D029968:Escherichia coli Proteins / Q000096:biosynthesis* / Q000737:chemistry / Q000235:genetics* / Q000302:isolation & purification; D005260:Female; D022761:Gene Transfer, Horizontal; D006801:Humans; D007525:Isoelectric Focusing; D007526:Isoelectric Point; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D010957:Plasmids; D017422:Sequence Analysis, DNA; D018440:beta-Lactam Resistance; D001618:beta-Lactamases / Q000096:biosynthesis* / Q000737:chemistry / Q000235:genetics* / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D004269:DNA, Bacterial; D029968:Escherichia coli Proteins; C048795:AmpC beta-lactamases; D001618:beta-Lactamases
Antimicrob Agents Chemother. 2000 Jun;44(6):1438-42
10817689
Antimicrob Agents Chemother. 2004 Feb;48(2):533-7
14742206
Antimicrob Agents Chemother. 1995 Jun;39(6):1211-33
7574506
Diagn Microbiol Infect Dis. 1998 Jul;31(3):461-6
9635237
Acta Pharmacol Sin. 2008 Feb;29(2):217-25
18215351
JAMA. 2000 Dec 27;284(24):3151-6
11135779
Antimicrob Agents Chemother. 1997 Mar;41(3):563-9
9055993
J Antimicrob Chemother. 1996 Jul;38(1):127-32
8858464
Antimicrob Agents Chemother. 2001 Aug;45(8):2269-75
11451684
Antimicrob Agents Chemother. 2002 Jan;46(1):1-11
11751104
J Antimicrob Chemother. 1995 Jan;35(1):235-6
7768779
Antimicrob Agents Chemother. 1999 May;43(5):1206-10
10223937
Antimicrob Agents Chemother. 1995 Oct;39(10):2269-75
8619581
J Bacteriol. 1981 Mar;145(3):1365-73
7009583
J Clin Microbiol. 1997 Feb;35(2):508-10
9003629
Antimicrob Agents Chemother. 1990 Nov;34(11):2200-9
1963529
Annu Rev Microbiol. 1991;45:37-67
1741619
Philos Trans R Soc Lond B Biol Sci. 1980 May 16;289(1036):321-31
6109327
Yonsei Med J. 1998 Dec;39(6):520-5
10097678
Antimicrob Agents Chemother. 1980 Jun;17(6):1001-3
6250465